Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer (Q33369094)

26 July 2017

title

Phase II study of pemetrexed in combination with carboplatin in the first-line treatment of advanced nonsmall cell lung cancer (English)

1 reference

26 July 2017

1 reference

1 reference

Gregory W Gladish

0 references

Roy S Herbst

1 reference

Vassiliki Papadimitrakopoulou

26 July 2017

object named as

Vassiliki A Papadimitrakopoulou

1 reference

26 July 2017

George R Blumenschein

object named as

George R Blumenschein

1 reference

26 July 2017

Frank V Fossella

1 reference

26 July 2017

Bonnie S Glisson

1 reference

26 July 2017

Ralph G Zinner

1 reference

26 July 2017

Katherine M W Pisters

1 reference

26 July 2017

Edward S Kim

1 reference

26 July 2017

Yun W Oh

1 reference

26 July 2017

Beverly O Peeples

1 reference

26 July 2017

Zhishen Ye

1 reference

26 July 2017

Rafael E Curiel

1 reference

26 July 2017

Coleman K Obasaju

1 reference

26 July 2017

Waun K Hong

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 December 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

104

1 reference

26 July 2017

1 reference

26 July 2017

page(s)

2449-2456

1 reference

Understanding the cancer biology universe: enigmas, context and future prospects

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Design and synthesis of inhibitors of folate-dependent enzymes as antitumor agents.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: A phase II study. National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Phase II trial of pemetrexed disodium (ALIMTA, LY231514) in chemotherapy-naïve patients with advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, ALIMTA) and cisplatin: a multicenter phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Survival advantage for carboplatin substituting cisplatin in combination with vindesine and mitomycin C for stage IIIB and IV squamous-cell bronchogenic carcinoma: a randomized phase III study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Activity of gemcitabine and carboplatin in advanced non-small cell lung cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Multicenter phase II trial of docetaxel and carboplatin in patients with stage IIIB and IV non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Cisplatin-gemcitabine combination in advanced non-small-cell lung cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Clinical features of hypersensitivity reactions to carboplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21480

7 January 2021

Identifiers

DOI

10.1002/CNCR.21480

1 reference

release_tsxer3j7jrautam3zumaobm5xy

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/tsxer3j7jrautam3zumaobm5xy

24 November 2022

mapped directly with Wikidata item

1 reference